Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coronary artery disease in Turkish patients
1Özel Kent Hastanesi, Kardiyoloji Kliniği, İzmir
2From Department of Medical Biology and Genetics Faculty of Medicine, Celal Bayar University, Manisa, Turkey
3Department of Cardiology, School of Medicine, Celal Bayar University, Manisa, Turkey
4Department of Pediatrics, Faculty of Medicine, Ege University, İzmir
Anatol J Cardiol 2006; 6(2): 132-134 PubMed ID: 16766276
Full Text PDF

Abstract

Objective: Platelet-activating factor (PAF) is a phospholipid with multiple actions that is involved in inflammatory diseases as well as in athero- genesis. It is inactivated by a plasma enzyme, PAF-acetylhydrolase (PAF-AH). Deficiency of this enzyme in plasma is caused by a missense mutation in the gene (G994T). The aim of this study was to investigate association of this mutation with premature coronary artery disease (CAD). Methods: One hundred and fifteen unrelated Turkish patients with a diagnosis of premature CAD and 128 unrelated healthy subjects were enrolled in this study. Genotyping was performed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Results: The prevalence of the G994T mutation in the patients was 2.60 % (heterozygote), and 0 % in the controls. There was no significant difference in allele frequency and genotype distribution among the study groups. Conclusion: The G9943T mutation in the plasma PAF acetylhydrolase gene is not associated with premature CAD in Turkish subjects.